Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP

Condition:   Metastatic Breast Cancer Intervention:   Drug: PARP inhibitor 2X-121 Sponsors:   Oncology Venture;   Smerud Medical Research International AS;   Danish Breast Cancer Cooperative Group Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials